ReviewFrontiers in immunology2021
COVID-19 Disease and Dermatomyositis: A Mini-Review.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Anti-MDA5+ dermatomyositis following SARS-COV-2 infections: a systematic review.Frontiers in immunology · 2025Pooled it
- Anti-MDA5 Antibody Linking COVID-19, Type I Interferon, and Autoimmunity: A Case Report and Systematic Literature Review.Frontiers in immunology · 2022Pooled it
- Rhino-orbito-cerebral Rhizopus delemar infection in a patient with anti-melanoma differentiation-associated-5-positive dermatomyositis diagnosed by metagenomic next-generation sequencing: a case report.BMC infectious diseases · 2026Article
- Investigating the profile of patients with idiopathic inflammatory myopathies in the post-COVID-19 period.Microbiology spectrum · 2025Article
- When viral infections meet the anti-MDA5 antibody-positive dermatomyositis.Frontiers in immunology · 2025Review
- Neurophysiology and muscle histopathology in ICU-acquired muscle weakness: Lessons learned from COVID-19.Clinical neurophysiology practice · 2025Article
- Severe Edematous Facial Myositis Following Dual Influenza and COVID-19 Vaccination: A Case Report.Cureus · 2024Article
- Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis.Arthritis research & therapy · 2024Article
- Anti-MDA5 autoantibodies predict clinical dynamics of dermatomyositis following SARS-CoV-2 mRNA vaccination: a retrospective statistical analysis of case reports.Rheumatology international · 2024Review
- Atypical antinuclear matrix protein 2-positive dermatomyositis presenting with anasarca and bulbar weakness after COVID-19 infection requiring mechanical ventilation.Archives of rheumatology · 2024Article
- Dysregulated CD38 expression on T cells was associated with rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 positive dermatomyositis.Frontiers in immunology · 2024Article
- Postacute Sequelae of SARS-CoV-2: Musculoskeletal Conditions and Pain.Physical medicine and rehabilitation clinics of North America · 2023Review
- Infection, Dysbiosis and Inflammation Interplay in the COVID Era in Children.International journal of molecular sciences · 2023Review
- Case report: Unusual patient with dermatomyositis associated with SARS-CoV-2 infection.Frontiers in neurology · 2023Article
- COVID-19 musculoskeletal involvement in children.Frontiers in pediatrics · 2023Review
- Anti-MDA5 dermatomyositis: an update from bench to bedside.Current opinion in rheumatology · 2022Review
- The Cytokine Growth Differentiation Factor-15 and Skeletal Muscle Health: Portrait of an Emerging Widely Applicable Disease Biomarker.International journal of molecular sciences · 2022Review
- Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review.Rheumatology international · 2022Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a large number of deaths, and there is still no effective treatment. COVID-19 can induce a systemic inflammatory response, and its clinical manifestations are diverse. Recently, it has been reported that COVID-19 patients may develop myositis and interstitial pulmonary disease similar to dermatomyositis (DM). This condition is similar to the rapidly progressive interstitial lung disease associated with MDA5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.